Antidote for Factor Xa Anticoagulants.

Link to article at PubMed

Antidote for Factor Xa Anticoagulants.

N Engl J Med. 2015 Nov 11;

Authors: Connors JM

Oral anticoagulant options have exploded. Dabigatran, a direct thrombin inhibitor, was approved for use in the United States in 2010 for the prevention of stroke in patients with atrial fibrillation; this was rapidly followed by approval of the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban within 5 years. The drive for the development of these drugs stemmed from the burdens associated with the use of the anticoagulants that had previously been available for outpatient treatment - subcutaneous heparins and oral vitamin K antagonists. Although these new drugs represent an important advance in anticoagulation therapy, concern over the lack of . . .

PMID: 26559124 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *